stockrow
Friday 6 November 2026
Export TRAX’s income statement to Excel — free account
First Tracks Biotherapeutics, Inc.
TRAX Healthcare Biotechnology
- EPS
- +40.5%
- Free cash flow
- +55.9%
Quarter to September 2026, against a year earlier
47.78
2.35
+5.17%
Follow TRAX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Current Ratio |
+3 more quarters Free account |
10.20 | 8.74 | 14.28 | 9.16 |
Net Debt/EBITDA |
0.00 | 5.44 | 4.86 | 4.89 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | — | 0.00 | — | |
Operating CF/Net income |
— | 0.65 | 0.96 | 0.54 | |
Capex/Depreciation |
— | (0.15) | (0.07) | 0.00 | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
— | 0.00 | (0.91) | (0.48) | |
Cash per Share |
0.00 | 0.00 | 4.80 | 4.35 | |
Shareholders Equity per Share |
0.00 | 0.00 | 4.82 | 4.22 | |
Interest Debt per Share |
— | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 4.82 | 4.22 | |
Free Cash Flow |
— | (32.58) | (31.94) | (17.05) | |
Working Capital |
285.38 | 256.29 | 165.30 | 147.63 | |
Capital Expenditures |
— | (0.02) | (0.02) | 0.00 | |
Net Current Asset Value |
273.35 | 256.29 | 163.40 | 146.28 | |
| Other line items | |||||
Quick Ratio |
10.05 | 8.65 | 13.50 | 8.60 | |
Revenue per Share |
— | — | 0.00 | 0.00 | |
Operating CF per Share |
— | 0.00 | (0.91) | (0.48) | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Average Assets |
— | — | 91.57 | — | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026